Verley (formerly Bon Vivant)
Bon Vivant is a biotechnology company based in Lyon, France, that uses precision fermentation to produce milk proteins. These milk proteins are then used by food manufacturers to produce dairy products with identical nutritional characteristics, taste and texture to conventional dairy products, but with much less environmental impact.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
www.verley-food.com
Related News
Bon Vivant achieves self-affirmed GRAS status, notifying the FDA of its recombinant whey protein enabling commercialization in the U.S.
Bon Vivant, the French leader in animal-free dairy proteins, closes a €15M financing round, led by Sofinnova Partners and Sparkfood, to accelerate its precision fermentation offering for the dairy industry
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.